BIOC Financials 07/21/2014 23:01:57
Biocept, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue 134 109
Cost of Revenue 2,330 1,202
Gross Profit (2,196) (1,092)
Operating Expenses
Research and Development 3,087 6,562
Sales, General and Admin. 2,662 2,849
Non-Recurring Items - -
Other - -
Operating Income (7,944) (10,503)
Income From Continuing Operations
Add'l Income/Expense Items 782 432
Earnings Before Interest and Tax (7,162) (10,071)
Interest Expense 2,070 2,187
Earnings Before Tax (9,232) (12,259)
Income Tax 1 1
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (9,233) (12,260)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (9,233) (12,260)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (9,233) (12,260)
Biocept, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue 134 109
Cost of Revenue 2,330 1,202
Gross Profit (2,196) (1,092)
Operating Expenses
Research and Development 3,087 6,562
Sales, General and Admin. 2,662 2,849
Non-Recurring Items - -
Other - -
Operating Income (7,944) (10,503)
Income From Continuing Operations
Add'l Income/Expense Items 782 432
Earnings Before Interest and Tax (7,162) (10,071)
Interest Expense 2,070 2,187
Earnings Before Tax (9,232) (12,259)
Income Tax 1 1
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (9,233) (12,260)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (9,233) (12,260)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (9,233) (12,260)
